Candel Therapeutics, Inc. (CADL) has announced the pricing for its underwritten public offering, which includes 10,000,001 shares priced at $6 each, along with pre-funded warrants for an additional 3.333 million shares at $5.99 per warrant. The anticipated gross revenue from this offering stands at approximately $80 million. These funds are earmarked for further development of the company's product pipeline and general corporate activities. The transaction is projected to conclude around December 16. Furthermore, the company has provided underwriters with a 30-day option to acquire up to an additional 2 million shares at the initial public offering price.
The material has been provided by InstaForex Company - www.instaforex.com
The material has been provided by InstaForex Company - www.instaforex.com